Welcome to Dividend.com
Please help us personalize your experience.
Select the one that best describes you
Continue to site >
Trending ETFs

iShares Nasdaq Biotechnology ETF

etf
IBB
Dividend policy
Active
Price as of:
$158.77 -0.29 0%
primary theme
Health Care Sector Equity
IBB (ETF)

iShares Nasdaq Biotechnology ETF

Dividend policy
Active
Price as of:
$158.77 -0.29 0%
primary theme
Health Care Sector Equity
IBB (ETF)
iShares Nasdaq Biotechnology ETF
Dividend policy
Active
Price as of:
$158.77 -0.29 0%
primary theme
Health Care Sector Equity

IBB - Snapshot

Vitals

  • YTD Return 5.7%
  • 3 Yr Annualized Return 12.1%
  • 5 Yr Annualized Return 10.5%
  • Net Assets $10.2 B
  • Holdings in Top 10 47.2%

52 WEEK LOW AND HIGH

$159.06
$126.88
$172.60

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.45%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 34.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) N/A
  • IRA N/A

Fund Classification

  • Primary Theme Health Care Sector Equity
  • Fund Type Exchange Traded Fund
  • Investment Style Health

Compare IBB to Popular Health Care Sector Equity Funds

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$121.03

-1.12%

$17.26 B

1.19%

$1.45

blocked
blocked
blocked

8.15%

0.10%

Compare IBB to Popular Health Care Sector Equity ETFs

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$123.74

-1.14%

$27.65 B

1.36%

$1.70

blocked
blocked
blocked

9.96%

0.13%

$242.13

-1.08%

$17.26 B

1.19%

$2.90

blocked
blocked
blocked

9.55%

0.10%

$158.77

-0.18%

$10.16 B

0.18%

$0.28

blocked
blocked
blocked

5.75%

0.45%

$350.67

-0.65%

$7.83 B

0.26%

$0.93

blocked
blocked
blocked

8.41%

0.41%

$133.58

-0.60%

$6.76 B

0.24%

$0.32

blocked
blocked
blocked

-4.25%

0.35%

IBB - Profile

Distributions

  • YTD Total Return 4.8%
  • 3 Yr Annualized Total Return 12.1%
  • 5 Yr Annualized Total Return 10.5%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.24%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    iShares Nasdaq Biotechnology ETF
  • Fund Family Name
    iShares
  • Inception Date
    Feb 05, 2001
  • Shares Outstanding
    66950000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Greg Savage

Fund Description

The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.


IBB - Performance

Return Ranking - Trailing

Period IBB Return Category Return Low Category Return High Rank in Category (%)
YTD 5.7% -12.8% 23.4% 50.00%
1 Yr 12.9% -1.4% 110.6% 80.95%
3 Yr 12.1%* 3.2% 43.8% 74.32%
5 Yr 10.5%* 3.7% 37.4% 82.27%
10 Yr 15.6%* 8.4% 18.8% 39.84%

* Annualized

Return Ranking - Calendar

Period IBB Return Category Return Low Category Return High Rank in Category (%)
2020 25.7% -13.6% 178.2% 15.53%
2019 25.0% 3.8% 63.8% 23.45%
2018 -9.7% -49.7% 21.5% 68.61%
2017 -59.8% -59.8% 54.4% 100.00%
2016 -21.6% -36.6% 11.6% 82.03%

Total Return Ranking - Trailing

Period IBB Return Category Return Low Category Return High Rank in Category (%)
YTD 4.8% -12.8% 22.0% 54.65%
1 Yr 12.9% -1.4% 110.6% 77.38%
3 Yr 12.1%* 3.2% 43.8% 72.97%
5 Yr 10.5%* 3.7% 37.4% 79.43%
10 Yr 15.6%* 8.4% 18.8% 39.84%

* Annualized

Total Return Ranking - Calendar

Period IBB Return Category Return Low Category Return High Rank in Category (%)
2020 25.7% -13.6% 178.2% 15.53%
2019 25.0% 3.8% 63.8% 23.45%
2018 -9.7% -25.3% 22.2% 71.53%
2017 20.7% -10.8% 54.4% 53.33%
2016 -21.6% -36.6% 11.6% 88.28%

IBB - Holdings

Concentration Analysis

IBB Category Low Category High IBB % Rank
Net Assets 10.2 B 6.68 M 49.7 B 8.67%
Number of Holdings 282 25 506 4.05%
Net Assets in Top 10 4.77 B 1.53 M 19.3 B 6.36%
Weighting of Top 10 47.16% 8.9% 78.2% 18.50%

Top 10 Holdings

  1. Amgen Inc 8.80%
  2. Gilead Sciences Inc 6.97%
  3. Regeneron Pharmaceuticals Inc 6.51%
  4. Regeneron Pharmaceuticals Inc 6.51%
  5. Regeneron Pharmaceuticals Inc 6.51%
  6. Regeneron Pharmaceuticals Inc 6.51%
  7. Regeneron Pharmaceuticals Inc 6.51%
  8. Regeneron Pharmaceuticals Inc 6.51%
  9. Regeneron Pharmaceuticals Inc 6.51%
  10. Regeneron Pharmaceuticals Inc 6.51%

Asset Allocation

Weighting Return Low Return High IBB % Rank
Stocks
99.82% 82.66% 104.58% 23.70%
Cash
0.17% -0.13% 17.34% 72.25%
Preferred Stocks
0.00% 0.00% 5.23% 16.18%
Other
0.00% -26.05% 8.98% 35.84%
Convertible Bonds
0.00% 0.00% 0.02% 6.36%
Bonds
0.00% 0.00% 17.12% 8.67%

Stock Sector Breakdown

Weighting Return Low Return High IBB % Rank
Healthcare
100.00% 63.71% 100.00% 3.47%
Utilities
0.00% 0.00% 0.00% 5.78%
Technology
0.00% 0.00% 19.82% 19.08%
Real Estate
0.00% 0.00% 6.19% 12.72%
Industrials
0.00% 0.00% 6.41% 16.76%
Financial Services
0.00% 0.00% 3.21% 46.24%
Energy
0.00% 0.00% 0.00% 5.78%
Communication Services
0.00% 0.00% 8.10% 9.83%
Consumer Defense
0.00% 0.00% 29.47% 13.29%
Consumer Cyclical
0.00% 0.00% 14.16% 14.45%
Basic Materials
0.00% 0.00% 3.68% 38.15%

Stock Geographic Breakdown

Weighting Return Low Return High IBB % Rank
US
90.13% 58.55% 104.03% 27.17%
Non US
9.69% 0.00% 40.32% 56.65%

IBB - Expenses

Operational Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.45% 0.08% 7.05% 85.80%
Management Fee 0.46% 0.00% 1.25% 17.14%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 34.00% 3.00% 256.00% 34.57%

IBB - Distributions

Dividend Yield Analysis

IBB Category Low Category High IBB % Rank
Dividend Yield 0.04% 0.00% 0.96% 11.43%

Dividend Distribution Analysis

IBB Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annually Semi-Annually Annually

Net Income Ratio Analysis

IBB Category Low Category High IBB % Rank
Net Income Ratio 0.24% -2.54% 1.74% 34.71%

Capital Gain Distribution Analysis

IBB Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

IBB - Fund Manager Analysis

Managers

Greg Savage


Start Date

Tenure

Tenure Rank

Jan 01, 2008

13.42

13.4%

Greg Savage, Managing Director; has been associated with BlackRock Fund Advisors since 2009. Mr. Savage has been a senior portfolio manager for BFA and BTC since 2009. Prior to his employment with BFA and BTC, Mr. Savage was a senior portfolio manager from 2006 to 2009 for BGFA and BGI and a portfolio manager from 2001 to 2006 for BGFA and BGI.

Jennifer Hsui


Start Date

Tenure

Tenure Rank

Aug 01, 2012

8.84

8.8%

Jennifer Hsui has been employed by BlackRock Fund Advisors as a senior portfolio manager since 2007. Prior to that, Ms. Hsui was a portfolio manager from 2006 to 2007 for BGFA. She was a research analyst for RBC Capital Markets from 2003 to 2006.

Alan Mason


Start Date

Tenure

Tenure Rank

Apr 15, 2016

5.13

5.1%

Alan Mason is a Managing Director of BlackRock Advisors, LLC since 2009. Previously, Mr. Mason was a Managing Director of Barclays Global Investors from 2008 to 2009 and a Principal from 1996 to 2008.

Amy Whitelaw


Start Date

Tenure

Tenure Rank

Aug 01, 2018

2.83

2.8%

Amy Whitelaw is Managing Director of BlackRock, Inc. since 2013 and was Director of the firm from 2009 to 2012. Ms. Whitelaw's service with the firm dates back to 1998, including her years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Ms. Whitelaw served as Principal of BGI from 2000 to 2009. Previously Ms. Whitelaw worked in the Transition Services group as a transition manager and strategist, and was also an international equity trader on BGI’s trading desk.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.04 23.72 7.22 21.1